Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: April 2007
-
The University of Michigan's Life Sciences Institute is sponsoring a symposium for presentations and discussions relating to the latest in stem cell biology research. The symposium, entitled "Frontiers in Stem Cell Biology," will be held May 9, 2007 at the Biomedical Sciences Research Building Auditorium at the University of Michigan. More information, including the schedule…
-
By Sherri Oslick — In a recent press release, ARIAD Pharmaceuticals, Inc. announced that it has filed suit against Amgen Inc., certain Amgen affiliates, and Wyeth for infringement of U.S. Patent No. 6,410,516 ("Nuclear Factors Associated with Transcriptional Regulation," issued June 25, 2002). The ‘516 patent is directed to certain aspects of the…
-
By Kevin E. Noonan — The recent first Office Action in the re-examination of the Thomson stem cell patents before the U.S. Patent and Trademark Office (see "WARF Stem Cell Patent Claims Rejected in Re-examination") has predictably resulted in press releases and commentary regarding these patents. However, while the Patent Office has initially…
-
By Donald Zuhn — Osprey Pharmaceuticals Ltd. announced today that it had been granted U.S. Patent Nos. 7,157,418; 7,166,702; and 7,192,736. The claims of the ‘418 patent are directed to methods for treating secondary tissue damage and other inflammatory conditions and disorders using a chemokine-cell toxin conjugate, the claims of the ‘702 patent…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Teva Pharmaceutical Industries Ltd. et. al. v. Cobalt Pharmaceuticals, Inc. et. al.2:07-cv-01690; filed April 10, 2007 in the District Court of New…
-
April 16-18, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources Group) – Orlando, FL April 19-20, 2007 – "Litigation and Enforcement in the Biotech and Pharmaceutical Industry" (GTCbio) – San Francisco, CA April 27, 2007 – Patent Claim Construction Workshop (Law Seminars International) – Atlanta, GA May 6-9, 2007 – BIO International…
-
By Donald Zuhn — On Thursday, Dow Chemical Co. announced that two senior executives had been fired for "engag[ing] in business activity that was highly inappropriate and a clear violation of Dow’s Code of Business Conduct." In particular, Dow determined that the two executives had been "involved in unauthorized discussions with third parties…
-
By Jason Derry — Array BioPharma has announced that AstraZeneca has dosed a patient with its MEK inhibitor, ARRY-704, in a Phase I clinical trial. By dosing the first patient, Array BioPharma is now entitled to a $2 million milestone payment from AstraZeneca. ARRY-704 is an orally active MEK-inhibitor with tumor suppressive activity. …
-
By Donald Zuhn — On Thursday, Allergan, Inc. announced that the U.S. Court of Appeals for the Federal Circuit has affirmed judgment in favor of Allergan and Roche Palo Alto, LLC in a patent infringement suit against Apotex, Inc., Apotex Corp., and Novex Pharma ("Apotex"). As a result of this decision, Apotex will…
-
By Donald Zuhn — On Tuesday, Abbott announced that it had reached an agreement with World Health Organization (WHO) Director General Margaret Chan to reduce the price of its Kaletra/Aluvia (lopinavir/ritonavir) AIDS drugs in the developing world. In particular, Abbott will be offering the drugs to about forty low and low-middle income countries…
Patent Docs 